"Dihydropyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.
| Descriptor ID |
D004095
|
| MeSH Number(s) |
D03.383.725.203
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dihydropyridines".
Below are MeSH descriptors whose meaning is more specific than "Dihydropyridines".
This graph shows the total number of publications written about "Dihydropyridines" by people in this website by year, and whether "Dihydropyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 4 | 0 | 4 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dihydropyridines" by people in Profiles.
-
Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules. 2021 Mar 17; 26(6).
-
Dihydropyridine Calcium Channel Blockers and the Risk of Severe COVID-19. Chest. 2021 07; 160(1):89-93.
-
Synthetic Dihydropyridines as Novel Antiacanthamoebic Agents. Med Chem. 2020; 16(7):841-847.
-
Synthesis, in silico and in vitro studies of new 1,4-dihydropiridine derivatives for antitumor and P-glycoprotein inhibitory activity. Bioorg Chem. 2019 10; 91:103156.
-
Current perspective on the use of calcium channel blockers to treat hypertensive patients: the role of lercanidipine. Future Cardiol. 2019 07; 15(4):259-266.
-
Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2019 04; 37(4):844-850.
-
Effects on 24-hour blood pressure variability of ace-inhibition and calcium channel blockade as monotherapy or in combination. Sci Rep. 2018 09 13; 8(1):13779.
-
TRIM65 is a potential oncogenic protein via ERK1/2 on Jurkat and Raji cells: A therapeutic target in human lymphoma malignancies. Cell Biol Int. 2018 Nov; 42(11):1503-1510.
-
Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. J Virol. 2018 08 15; 92(16).
-
Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor. Nature. 2018 04; 556(7702):520-524.